WJA
ABBV icon

Willis Johnson & Associates’s AbbVie ABBV Stock Holding History

Willis Johnson & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$429K Buy
1,974
+6
+0.3% +$1.33K 0.03% 127
2025
Q4 		$450K Sell
1,968
-47
-2% -$10.7K 0.03% 109
2025
Q3 		$467K Buy
2,015
+171
+9% +$34.8K 0.03% 108
2025
Q2 		$342K Sell
1,844
-1,413
-43% -$263K 0.02% 117
2025
Q1 		$682K Sell
3,257
-122
-4% -$23.7K 0.05% 76
2024
Q4 		$600K Buy
3,379
+291
+9% +$53.5K 0.05% 85
2024
Q3 		$610K Sell
3,088
-100
-3% -$18.7K 0.05% 86
2024
Q2 		$547K Sell
3,188
-79
-2% -$13.1K 0.04% 87
2024
Q1 		$595K Sell
3,267
-11
-0.3% -$1.9K 0.05% 77
2023
Q4 		$508K Buy
3,278
+51
+2% +$7.43K 0.05% 77
2023
Q3 		$481K Buy
3,227
+825
+34% +$121K 0.05% 77
2023
Q2 		$324K Sell
2,402
-35
-1% -$5.13K 0.03% 97
2023
Q1 		$388K Buy
2,437
+127
+5% +$19.4K 0.05% 85
2022
Q4 		$373K Sell
2,310
-363
-14% -$55.7K 0.05% 82
2022
Q3 		$359K Sell
2,673
-343
-11% -$49.2K 0.05% 78
2022
Q2 		$462K Sell
3,016
-108
-3% -$16.5K 0.06% 72
2022
Q1 		$506K Buy
3,124
+788
+34% +$114K 0.07% 67
2021
Q4 		$316K Buy
2,336
+281
+14% +$33.2K 0.04% 77
2021
Q3 		$222K Sell
2,055
-173
-8% -$19.8K 0.03% 85
2021
Q2 		$251K Buy
2,228
+49
+2% +$5.52K 0.04% 78
2021
Q1 		$236K Buy
+2,179
New +$233K 0.04% 79

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Willis Johnson & Associates's ABBV Position: Q1 2026 in Review

Willis Johnson & Associates increased its AbbVie (ABBV) stake by 0.3% in Q1 2026, buying an estimated $1.33K and bringing the position to 1,974 shares worth $429K. The position accounts for 0.03% of the portfolio, ranked #127.

Willis Johnson & Associates first reported a position in ABBV in Q1 2021 and has held it in 21 quarters since. The position peaked at $682K in Q1 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Willis Johnson & Associates held 1,974 shares of AbbVie worth $429K as of Q1 2026.
  • Willis Johnson & Associates bought 6 AbbVie shares in Q1 2026, an estimated $1.33K.
  • AbbVie made up 0.03% of Willis Johnson & Associates's portfolio in Q1 2026, its #127 holding.
  • Willis Johnson & Associates first reported a position in AbbVie in Q1 2021 and has held it in 21 quarters since.
  • Willis Johnson & Associates's AbbVie position peaked at $682K in Q1 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Willis Johnson & Associates's 13F filing for Q1 2026, filed 23 Apr 2026.